Gilead Sciences, Inc. $GILD Shares Sold by APG Asset Management N.V.

APG Asset Management N.V. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,055,571 shares of the biopharmaceutical company’s stock after selling 103,565 shares during the quarter. APG Asset Management N.V. owned 0.09% of Gilead Sciences worth $117,168,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in GILD. Trivium Point Advisory LLC lifted its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares in the last quarter. Rothschild Investment LLC increased its position in Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after purchasing an additional 84 shares in the last quarter. Hemington Wealth Management raised its holdings in Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 85 shares during the period. Ignite Planners LLC lifted its position in Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after buying an additional 86 shares in the last quarter. Finally, Archer Investment Corp lifted its position in Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares of the company’s stock, valued at $92,086,800. This trade represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 299,280 shares of company stock valued at $42,487,570. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 3.6%

NASDAQ:GILD opened at $148.95 on Friday. The stock has a market cap of $184.91 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 1.95 and a beta of 0.36. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.31 and a current ratio of 1.55. The business’s 50-day simple moving average is $136.10 and its 200 day simple moving average is $124.81.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the firm earned $1.90 EPS. Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is presently 46.68%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Argus increased their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Daiwa Securities Group upped their price target on shares of Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday. The Goldman Sachs Group increased their price target on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. Cantor Fitzgerald boosted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $156.72.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead highlighted a twice-yearly HIV prevention injection with reported 99.9% efficacy (executive interview), reinforcing the company’s long-acting HIV/IP prevention market potential and upside to future sales if uptake and approvals follow. Johanna Mercier on Gilead’s HIV prevention innovation
• Positive Sentiment: New Phase 3 ARTISTRY-1 and ARTISTRY-2 data show the investigational single-tablet bictegravir/lenacapavir (BIC/LEN) maintained virological suppression when patients switched regimens — strengthens pipeline value and switch-market potential. Gilead’s Single-Tablet Regimen Maintained Virological Suppression
• Positive Sentiment: Daiwa raised its price target to $161 and kept an “outperform” rating, signaling buy-side confidence and giving shares technical/analyst momentum. Daiwa Securities Adjusts Price Target on Gilead Sciences
• Positive Sentiment: UBS reiterated a Buy with a $175 target, citing the advancing long-acting HIV franchise — another supportive analyst endorsement for upside. Gilead Sciences: Advancing Long-Acting HIV Franchise
• Positive Sentiment: Zacks issued a series of upward revisions to Gilead’s FY2026–FY2028 and multiple quarterly EPS forecasts (raises across 2026–2028), which supports higher medium-term earnings expectations. Zacks Research GILD Estimates
• Neutral Sentiment: Coverage pieces note Gilead has been outperforming the healthcare sector recently and analysts remain optimistic — supports momentum but is descriptive rather than new fundamental news. Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
• Neutral Sentiment: Industry/peer updates such as Kymera’s results were reported but are not directly material to Gilead’s near-term outlook. Kymera Therapeutics Q4 Highlights
• Negative Sentiment: Zacks trimmed its Q3 2026 EPS estimate slightly (from $2.34 to $2.30) — a small near-term downgrade within otherwise stronger multi-year raises; worth monitoring for quarterly variability. Zacks Lowers Q3 2026 Estimate
• Negative Sentiment: Merck reported promising Phase 3 results for a two-drug HIV regimen that matched Gilead’s Biktarvy, representing competitive pressure if approved. Investors should monitor regulatory outcomes and market-share implications. Merck’s New HIV Drug Shows Promise

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.